Glyceryl monostearate 40–55 (compendial descriptor: glyceryl monostearate 40–55, Ph. Eur. 0495; USP-NF Glyceryl Monostearate) is a non-ionic amphiphilic lipid excipient supplied as a micronized or prilled powder. Representative product models include GMS-PH-40/55-M, a micronized variant with a volume median diameter d50 of 12–25 µm measured by laser diffraction (Ph. Eur. 2.9.31 / USP <429>), and GMS-PH-40/55-P, a prilled variant with a d50 of 250–400 µm for melt granulation. The monoacylglycerol fraction is controlled at 40.0–55.0% on an anhydrous basis; acid value is limited to ≤ 3.0 (Ph. Eur. 2.5.1), free glycerol to ≤ 6.0%, iodine value to ≤ 3.0 (Ph. Eur. 2.5.4), and water to ≤ 1.0% (Ph. Eur. 2.5.12). The manufacturing route is direct esterification of glycerol with stearic acid followed by wiped-film molecular distillation and nitrogen-flushed finishing; residual solvent and elemental impurity control follow ICH Q3C and ICH Q3D. The powder is packed in nitrogen-flushed double polyethylene bags inside triple-wall drums, with recommended storage at 15–25 °C and ≤ 60% RH.

What Limits Direct Compression Lubricant Efficiency at High Press Speed?

On high-speed rotary tablet presses operating at 60–100 rpm, the micronized grade is blended at 1.0–3.0 wt% in a diffusion blender for 3–5 min after a pre-blend step. The platelet morphology aligns under compression and lowers die-wall friction; on instrumented rotary presses, ejection force typically falls by 40–60% relative to an unlubricated formulation, although published data for specific machine model–blend time combinations is limited. Over-lubrication is a processing boundary: blend times exceeding 15 min can produce a continuous hydrophobic film on the granule surface and reduce tablet tensile strength below 1.5 MPa, with consequent friability failures under USP <1216>. Disintegration time is tracked by USP <701>, dissolution by USP <711>, and powder flow by USP <1174>. The low acid value of ≤ 3.0 is relevant for acid-labile active ingredients and distinguishes this material from stearic acid-based lubricants with higher free fatty acid content.

Hard gelatin capsule filling at production speed uses the micronized grade at 0.5–1.5 wt% before the dosator or tamping-pin stage. Blends with a compressibility index below 15% under USP <1174> are generally acceptable for tamping-pin machines, whereas higher-friction blends may require forced feeding. Over-mixing can delay capsule dissolution because hydrophobic surface coverage increases; dissolution is tested under USP <711> with sinkers as described in USP <1094>. For lipid-based semi-solid fills, the prilled grade is dissolved at 60–70 °C in the oily vehicle and cooled to form a thixotropic matrix; viscosity at 25 °C is measured by cone-and-plate rheometry under ISO 3219.

In melt granulation, the prilled grade GMS-PH-40/55-P is heated to 60–70 °C in a jacketed high-shear mixer at 2.0–5.0 wt% binder load. The melting range of 54–64 °C (capillary method, Ph. Eur. 2.2.14) requires the powder bed to remain above 55 °C during binder distribution; otherwise, solidification as low-melting α-form platelets generates fines after milling, with d10 below 50 µm. Impeller tip speed of 4–6 m/s and jacket temperature of 65 °C are typical starting conditions, with endpoint tracked by torque and product temperature rather than time alone. Granule flow is characterized by Hausner ratio 1.12–1.20 and Carr index 12–18% under USP <1174>. Particle size distribution is confirmed by laser diffraction per Ph. Eur. 2.9.31; tablets compressed from these granules are tested for weight uniformity under Ph. Eur. 2.9.5. Because the monoester is hydrophobic, water-based wet granulation is not the primary application; the material is added post-drying as a lubricant at 1.0–2.0 wt% where granule friability must be limited.

Melt Granulation and Sustained-Release Matrix Behaviour Require Melting Range, Not HLB Alone

The non-ionic monoester carries an HLB of approximately 3.8 and forms water-in-oil structures; in sustained-release matrices, this low HLB retards water penetration and supports erosion-diffusion control. Matrix tablets containing 5.0–15.0 wt% GMS compressed at 8–12 kN are evaluated in dissolution Apparatus 2 at 50 rpm (USP <711>) in 0.1 M HCl and phosphate buffer pH 6.8. The controlling variable is not HLB alone but the fraction of β-polymorph and the melting interval of the specific monoacylglycerol composition; storage above 40 °C accelerates polymorphic conversion and alters erosion rate, so release specifications are established per product under ICH Q6A and development guidance in USP <1092>. For liquid-filled hard capsules, the material at 5.0–10.0 wt% creates thixotropic structure in medium-chain triglycerides. The prilled grade is preferred in this application because the larger particle size reduces dust and simplifies molten dispersion, while the micronized grade may agglomerate in low-shear mixers.

For aqueous injection formulations containing GMS as a co-emulsifier, high-shear dispersion is required. The lipid phase is heated to 60–70 °C; GMS-PH-40/55-INJ is combined with egg lecithin or polysorbate 80 at 0.5–1.5 wt% of the final emulsion. Primary rotor-stator mixing is followed by high-pressure homogenization at 800–1000 bar, reducing mean droplet size to 200–300 nm. Globule size distribution is controlled by USP <729>, particulate matter by USP <788> and Ph. Eur. 2.9.19, and bacterial endotoxins by USP <85> and Ph. Eur. 2.6.14. The injectable grade is released with an endotoxin limit of ≤ 0.05 EU/mg unless the maximum daily dose and administration route justify a different limit. Peroxide value is measured by Ph. Eur. 2.5.5; nitrogen-flushed packaging and a retest interval of 24 months at 25 °C/60% RH are used to control oxidative degradation. The oral-grade material is not interchangeable with the injectable grade because bioburden and endotoxin controls are route-specific and cannot be established by terminal dry blending.

When Injectable Lipid Emulsions Demand Low Endotoxin and Low Peroxide Inputs

When the lipid excipient is incorporated into a terminal-sterilized emulsion, the dry powder must be selected and handled to avoid pre-existing endotoxin, because steam sterilization at 121 °C for 15 min or 115 °C for 30 min (Ph. Eur. 5.1.1) does not destroy endotoxin. The injectable grade is double-bagged and nitrogen-flushed in triple-wall drums; each container is sampled for bioburden, endotoxin, and peroxide value. Dry-heat depyrogenation at 160 °C for 2 h is possible only with validation because the low melting range of 54–64 °C makes the powder prone to fusion and polymorphic change; published data for this specific configuration is limited. For aseptic manufacture, the formulated emulsion is passed through a 0.22 µm sterile filter after high-pressure homogenization, and filter integrity is tested according to ASTM F838-20. Dry powder gamma irradiation under ISO 11137 may be used for a sterile grade, but free-radical formation must be monitored by peroxide value and iodine value after irradiation.

Technical-grade glyceryl monostearate used in polymer processing differs from the pharma grade in residual solvent limits under ICH Q3C, elemental impurity limits under ICH Q3D, microbial limits under Ph. Eur. 5.1.4, and batch-to-batch fatty acid composition. Technical material may exhibit acid values above 6.0 and transition-metal residues that catalyse lipid peroxidation; these are not acceptable in injectable lipid emulsions. Against magnesium stearate, GMS does not introduce magnesium ions and shows less effect on disintegration time at comparable lubrication performance, although it must be used at 1.0–3.0 wt% rather than 0.25–1.0 wt%. Against glyceryl dibehenate, the shorter C18 chain and lower melting range reduce thermal exposure during hot-melt granulation but produce faster matrix erosion and less pronounced sustained release. Against purified glyceryl monostearate 90, the 40–55 grade contains a controlled fraction of di- and triacylglycerols that influence crystallinity and melting behaviour more than monoester content alone. Against synthetic polyoxyethylene surfactants, GMS avoids ethylene oxide residual limits and has a different toxicological profile; however, its low HLB of 3.8 requires a high-HLB co-emulsifier in aqueous formulations. The self-emulsifying model GMS-PH-40/55-SE contains sodium or potassium stearate at 3–6% and is restricted to oral or topical use; the injectable grade excludes added stearate salts to maintain defined electrolyte content.